The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies NATICK, Mass., Boston Scientific Corporation has received CE Mark ...

The REBEL bare metal stent is similar to the company’s drug-eluting PROMUS Premier stent system, but without Everolimus – a biological therapy drug that treats advanced kidney cancer ...

A who's who of medical device outfits have taken to Paris this week for EuroPCR, flaunting their latest data and devices to a gathering of the continent's interventional cardiovascular specialists.

Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up ...

Subsequent to the approval, this next-generation durable polymer drug-eluting stent, Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System was launched in the U.S. The company ...

Boston Scientific ($BSX) rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan. The everolimus-releasing platinum-chromium stent ...

Boston Scientific's Promus Premier coronary stent--Courtesy of Boston Scientific The Massachusetts device company, which has been looking for a blockbuster product to kick-start revenue growth ...

and Promus Premier lines of stents. Boston Scientific generated $1.36 billion in worldwide sales of coronary stent systems in 2012, or approximately 19% of its total net sales. OrbusNeich's CEO ...

NATICK, Mass., Feb. 12, 2013 /PRNewswire/ -- Boston Scientific Corporation has received CE Mark approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System ...

While we are encouraged with the approval of Promus PREMIER in the U.S., Boston Scientific’s Interventional Cardiology segment has been recording declining sales over the past few quarters ...

The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies ... Mark approval for the Promus PREMIER™ Everolimus-Eluting ...

NATICK, Mass., Feb. 12, 2013 -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System ...